je.st
news
Tag: vertex
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex ...
2014-11-10 00:33:03| Semiconductors - Topix.net
According to GuruFocus Insider Data , the recent CFO sales were: Texas Instruments Inc, Royal Caribbean Cruises Ltd, and Vertex Pharmaceuticals Inc. On 11/03/2014, Sr. Vice President and CFO Kevin P. March sold 318,750 shares at an average price of $50.01. The price of the stock has increased by 1.78% since.
Tags: instruments
texas
weekly
royal
UPDATE 1-FDA panel votes to expand use of Vertex cystic fibrosis drug
2014-10-22 07:30:16| Biotech - Topix.net
A U.S. Food and Drug Administration advisory panel on Tuesday voted 13-2 to recommend expanding approval of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco to include a wider range of patients with the rare lung disease, the company said. The panel of experts said Kalydeco should be approved for patients ages 6 and older with a specific mutation of the R117H gene, of which there are about 500 people in the United States.
Tags: update
panel
expand
drug
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc.
2014-10-06 09:33:37| Footwear - Topix.net
On 08/20/2014, CFO David M Wehner sold 11,533 shares at an average price of $74.96. The price of the stock has increased by 3.5% since.
Vertex to stop selling hepatitis C drug Incivek, once a blockbuster, in October
2014-08-13 07:02:43| Biotech - Topix.net
Incivek was the first approved drug for Vertex in 2011, but it was quickly overwhelmed by competition from other hepatitis C treatment, including Gilead's Sovaldi.
Vertex Submits Supplemental New Drug Application (sNDA) To U.S. Food And Drug Administration For Use Of KALYDECO (ivacaftor) In People 18 And Older With Cystic Fibrosis Who Have The R117H Mutation
2014-07-02 10:30:30| drugdiscoveryonline Home Page
Vertex Pharmaceuticals Incorporated recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of KALYDECO in people with cystic fibrosis (CF) ages 18 and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene